459 related articles for article (PubMed ID: 25096612)
1. Effects of Alzheimer's disease-associated risk loci on cerebrospinal fluid biomarkers and disease progression: a polygenic risk score approach.
Martiskainen H; Helisalmi S; Viswanathan J; Kurki M; Hall A; Herukka SK; Sarajärvi T; Natunen T; Kurkinen KM; Huovinen J; Mäkinen P; Laitinen M; Koivisto AM; Mattila KM; Lehtimäki T; Remes AM; Leinonen V; Haapasalo A; Soininen H; Hiltunen M
J Alzheimers Dis; 2015; 43(2):565-73. PubMed ID: 25096612
[TBL] [Abstract][Full Text] [Related]
2. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
[TBL] [Abstract][Full Text] [Related]
4. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
Susanto TA; Pua EP; Zhou J;
J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
[TBL] [Abstract][Full Text] [Related]
5. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology.
Mulder SD; van der Flier WM; Verheijen JH; Mulder C; Scheltens P; Blankenstein MA; Hack CE; Veerhuis R
J Alzheimers Dis; 2010; 20(1):253-60. PubMed ID: 20164582
[TBL] [Abstract][Full Text] [Related]
6. Stability of CSF beta-amyloid(1-42) and tau levels by APOE genotype in Alzheimer patients.
Huey ED; Mirza N; Putnam KT; Soares H; Csako G; Levy JA; Copenhaver B; Cohen RM; Sunderland T
Dement Geriatr Cogn Disord; 2006; 22(1):48-53. PubMed ID: 16682793
[TBL] [Abstract][Full Text] [Related]
7. Preclinical cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers in Swedish familial Alzheimer's disease.
Thordardottir S; Ståhlbom AK; Ferreira D; Almkvist O; Westman E; Zetterberg H; Eriksdotter M; Blennow K; Graff C
J Alzheimers Dis; 2015; 43(4):1393-402. PubMed ID: 25182737
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide association reveals genetic effects on human Aβ42 and τ protein levels in cerebrospinal fluids: a case control study.
Han MR; Schellenberg GD; Wang LS;
BMC Neurol; 2010 Oct; 10():90. PubMed ID: 20932310
[TBL] [Abstract][Full Text] [Related]
9. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.
Martínez-Morillo E; Hansson O; Atagi Y; Bu G; Minthon L; Diamandis EP; Nielsen HM
Acta Neuropathol; 2014 May; 127(5):633-43. PubMed ID: 24633805
[TBL] [Abstract][Full Text] [Related]
10. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
[TBL] [Abstract][Full Text] [Related]
11. Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease.
Alcolea D; Martínez-Lage P; Sánchez-Juan P; Olazarán J; Antúnez C; Izagirre A; Ecay-Torres M; Estanga A; Clerigué M; Guisasola MC; Sánchez Ruiz D; Marín Muñoz J; Calero M; Blesa R; Clarimón J; Carmona-Iragui M; Morenas-Rodríguez E; Rodríguez-Rodríguez E; Vázquez Higuera JL; Fortea J; Lleó A
Neurology; 2015 Aug; 85(7):626-33. PubMed ID: 26180139
[TBL] [Abstract][Full Text] [Related]
12. Genetic variants of GSK3B are associated with biomarkers for Alzheimer's disease and cognitive function.
Kettunen P; Larsson S; Holmgren S; Olsson S; Minthon L; Zetterberg H; Blennow K; Nilsson S; Sjölander A
J Alzheimers Dis; 2015; 44(4):1313-22. PubMed ID: 25420549
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
[TBL] [Abstract][Full Text] [Related]
14. Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease.
Ewers M; Zhong Z; Bürger K; Wallin A; Blennow K; Teipel SJ; Shen Y; Hampel H
Brain; 2008 May; 131(Pt 5):1252-8. PubMed ID: 18334538
[TBL] [Abstract][Full Text] [Related]
15. Effects of Alzheimer's Disease-Associated Risk Loci on Amyloid-β Accumulation in the Brain of Idiopathic Normal Pressure Hydrocephalus Patients.
Laiterä T; Paananen J; Helisalmi S; Sarajärvi T; Huovinen J; Laitinen M; Rauramaa T; Alafuzoff I; Remes AM; Soininen H; Haapasalo A; Jääskeläinen JE; Leinonen V; Hiltunen M
J Alzheimers Dis; 2017; 55(3):995-1003. PubMed ID: 27802227
[TBL] [Abstract][Full Text] [Related]
16. Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers.
Kester MI; Goos JD; Teunissen CE; Benedictus MR; Bouwman FH; Wattjes MP; Barkhof F; Scheltens P; van der Flier WM
JAMA Neurol; 2014 Jul; 71(7):855-62. PubMed ID: 24818585
[TBL] [Abstract][Full Text] [Related]
17. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
[TBL] [Abstract][Full Text] [Related]
18. CSF biomarkers for Alzheimer's Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival.
Wallin AK; Blennow K; Andreasen N; Minthon L
Dement Geriatr Cogn Disord; 2006; 21(3):131-8. PubMed ID: 16391474
[TBL] [Abstract][Full Text] [Related]
19. Transcriptomics and mechanistic elucidation of Alzheimer's disease risk genes in the brain and in vitro models.
Martiskainen H; Viswanathan J; Nykänen NP; Kurki M; Helisalmi S; Natunen T; Sarajärvi T; Kurkinen KM; Pursiheimo JP; Rauramaa T; Alafuzoff I; Jääskeläinen JE; Leinonen V; Soininen H; Haapasalo A; Huttunen HJ; Hiltunen M
Neurobiol Aging; 2015 Feb; 36(2):1221.e15-28. PubMed ID: 25281018
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
